Compare Inovio Pharmaceuticals Inc (INO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Workiva Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: Workiva Inc is far larger — about 35.7× Inovio Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Workiva Inc for 21 Days on average.
| INO | WK | |
|---|---|---|
Market Cap | $112.19M | $4.01B |
Volume | 3,201,278 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $2.60 | $93.31 |
52-Week Low | $0.66 | $44.31 |
Typical Hold Time | 43 Days | 21 Days |
Enterprise Value | $83.51M | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Workiva (WK) trades at $73.69, up 3.02% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $86.00. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit, reflecting improved operational efficiency and strong gross margins of 80.21%.
The stock presents a growth opportunity driven by AI product innovations and positive analyst sentiment, but high valuation multiples (P/E of 87.73) and competitive pressures pose risks. Upside potential exists if earnings momentum continues, though investors should monitor execution against guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
